Results 141 to 150 of about 195,462 (245)

The Disquiet of Quiet Quitting: Definitional Clarity, Theoretical Pathways, and Future Research

open access: yesHuman Resource Management, EarlyView.
ABSTRACT Quiet quitting (QQ) has emerged as a prominent topic in both popular press and academic research, reflecting shifts in employees' engagement, effort allocation, and responses to contemporary work pressures. This review synthesizes findings from 11 papers published in a recent Special Issue on The Disquiet of Quiet Quitting.
Solon Magrizos   +5 more
wiley   +1 more source

Cancer pattern in Bhutan (2014–2022): Findings from population‐based cancer registry—A pathway to monitor cancer control activities

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The establishment in 2014 of the population‐based cancer registry (PBCR) of Bhutan created new opportunities for understanding national cancer trends, which previously were anticipated from data in neighbouring countries. This study presents the first nine‐year summary of cancer patterns in Bhutan, derived from PBCR data. From 2014 to 2022,
Phub Tshering   +9 more
wiley   +1 more source

Correction: Perception of obstetric violence and risk of post-traumatic stress disorder at 6 months postpartum: an observational study. [PDF]

open access: yesFront Psychol
Ortiz-Esquinas I   +5 more
europepmc   +1 more source

Educational inequalities in cervical cancer mortality in the Baltic countries and Finland in the context of organized screening: A register‐based study 2000–2015

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This study shows that absolute and relative educational inequalities in cervical cancer mortality are much larger in the Baltic countries than in Finland, where an organized screening programme was introduced more than 40 years earlier. After the introduction of organized screening, cervical cancer mortality declined among low‐educated ...
Oskar Nõmm   +7 more
wiley   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching   +20 more
wiley   +1 more source

Correction: Research priorities of the European Society of Clinical Pharmacy (ESCP): a questionnaire-based study. [PDF]

open access: yesInt J Clin Pharm
Okuyan B   +12 more
europepmc   +1 more source

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy‐related genes influence MGUS susceptibility.
José Manuel Sánchez‐Maldonado   +54 more
wiley   +1 more source

Home - About - Disclaimer - Privacy